Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 16, 2013Inflammatory Bowel DiseasesOpen Access

Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

APAsit ParikhJohns Hopkins UniversityIFIrving H. FoxTakeda (United States)TLTimothy LeachForest Institute

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Parikh et al. (2013) studied this question.

synapsesocial.com/papers/6a854742e1eabc68e2929528https://doi.org/10.1097/mib.0b013e318281f538
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study2011 · 212 citations
  2. 2The development of experimental autoimmune encephalomyelitis in the mouse requires alpha4-integrin but not alpha4beta7-integrin.1998 · 204 citations
  3. 3Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes.1994 · 358 citations
  4. 4Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates2012 · 138 citations